Spotlight on Neurology
MS Forum® VIII: Biomarkers, Imaging, and Gender-Based Issues in MS
StartActivity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
- Incorporate knowledge of the benefit/risk profiles of disease modifying therapies (DMTs), including COVID-19-related safety issues, when making decisions about early treatment for patients with MS.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering imaging and biomarkers, gender-based issues in patients with MS, as well as a series of TED talks on where the field is now and where it is heading.
Agenda
Introduction
Patricia K. Coyle, MD
Updates in Imaging and Biomarkers
Clyde E. Markowitz, MD
Gender-Based Issues in MS
Patricia K. Coyle, MD
Clinical Case: Journey of a Female MS Patient Through the Various
Phases of the Family Planning Process
Patricia K. Coyle, MD
TED Talks in MS: Where We Are, Where We’re Headed
Moderated by Bruce A. Cohen, MD, and Clyde E. Markowitz, MD
Panel Discussion
All Faculty
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
Activity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
- Incorporate knowledge of the benefit/risk profiles of disease modifying therapies (DMTs), including COVID-19-related safety issues, when making decisions about early treatment for patients with MS.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering imaging and biomarkers, gender-based issues in patients with MS, as well as a series of TED talks on where the field is now and where it is heading.
Agenda
Introduction
Patricia K. Coyle, MD
Updates in Imaging and Biomarkers
Clyde E. Markowitz, MD
Gender-Based Issues in MS
Patricia K. Coyle, MD
Clinical Case: Journey of a Female MS Patient Through the Various
Phases of the Family Planning Process
Patricia K. Coyle, MD
TED Talks in MS: Where We Are, Where We’re Headed
Moderated by Bruce A. Cohen, MD, and Clyde E. Markowitz, MD
Panel Discussion
All Faculty
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
Neurology Presentations
MS Forum® VIII: Novel Advances and the Optimization of MS Treatments
StartActivity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging disease-modifying therapies (DMTs) for the treatment of patients with MS.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging DMTs for the treatment of patients with MS.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic and case presentations covering vaccines in MS, differentiating DMTs, novel advances in MS, as well as a focus on Bruton tyrosine kinase inhibitors.
Agenda
Introduction – Overview of objectives and activation of
learning
Patricia K. Coyle, MD
The Year in Review: Novel Advances in MS
Clyde E. Markowitz, MD
Vaccines in MS: Immunization Protocols in
Patients With MS
Bruce A. Cohen, MD
Clinical Cases: Vaccination
Vacillation
Bruce A. Cohen, MD
Differentiating DMTs to Optimize Treatment
Individualization
Stephen Krieger, MD
Focus on BTK Inhibitors: Clinical Updates
Patricia K. Coyle, MD
Clinical Case: Selecting Optimal Treatment for a Patient With
MS
Patricia K. Coyle, MD
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY
Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
Activity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging disease-modifying therapies (DMTs) for the treatment of patients with MS.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging DMTs for the treatment of patients with MS.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic and case presentations covering vaccines in MS, differentiating DMTs, novel advances in MS, as well as a focus on Bruton tyrosine kinase inhibitors.
Agenda
Introduction – Overview of objectives and activation of
learning
Patricia K. Coyle, MD
The Year in Review: Novel Advances in MS
Clyde E. Markowitz, MD
Vaccines in MS: Immunization Protocols in
Patients With MS
Bruce A. Cohen, MD
Clinical Cases: Vaccination
Vacillation
Bruce A. Cohen, MD
Differentiating DMTs to Optimize Treatment
Individualization
Stephen Krieger, MD
Focus on BTK Inhibitors: Clinical Updates
Patricia K. Coyle, MD
Clinical Case: Selecting Optimal Treatment for a Patient With
MS
Patricia K. Coyle, MD
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY
Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
MS Forum® VIII: Biomarkers, Imaging, and Gender-Based Issues in MS
StartActivity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
- Incorporate knowledge of the benefit/risk profiles of disease modifying therapies (DMTs), including COVID-19-related safety issues, when making decisions about early treatment for patients with MS.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering imaging and biomarkers, gender-based issues in patients with MS, as well as a series of TED talks on where the field is now and where it is heading.
Agenda
Introduction
Patricia K. Coyle, MD
Updates in Imaging and Biomarkers
Clyde E. Markowitz, MD
Gender-Based Issues in MS
Patricia K. Coyle, MD
Clinical Case: Journey of a Female MS Patient Through the Various
Phases of the Family Planning Process
Patricia K. Coyle, MD
TED Talks in MS: Where We Are, Where We’re Headed
Moderated by Bruce A. Cohen, MD, and Clyde E. Markowitz, MD
Panel Discussion
All Faculty
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
Activity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
- Incorporate knowledge of the benefit/risk profiles of disease modifying therapies (DMTs), including COVID-19-related safety issues, when making decisions about early treatment for patients with MS.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering imaging and biomarkers, gender-based issues in patients with MS, as well as a series of TED talks on where the field is now and where it is heading.
Agenda
Introduction
Patricia K. Coyle, MD
Updates in Imaging and Biomarkers
Clyde E. Markowitz, MD
Gender-Based Issues in MS
Patricia K. Coyle, MD
Clinical Case: Journey of a Female MS Patient Through the Various
Phases of the Family Planning Process
Patricia K. Coyle, MD
TED Talks in MS: Where We Are, Where We’re Headed
Moderated by Bruce A. Cohen, MD, and Clyde E. Markowitz, MD
Panel Discussion
All Faculty
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
MS Forum® VIII: Updates on Progressive MS, the Patient Perspective, and MS Management in the COVID-19 Era
StartActivity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
- Determine treatment for patients with RRMS or progressive MS based on evidence-based recommendations.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering the effect of environmental factors and comorbidities in patients with MS, advances in progressive MS, as well as rapid-fire controversies in MS. This session will also feature the patient perspective, with video segments of a patient with MS addressing common concerns and the role of shared decision-making.
Agenda
Introduction
Patricia K. Coyle, MD
Patient Perspectives in MS
Patricia K. Coyle, MD and Dana Hernandez
Advances in Progressive MS: Optimizing Patient Recognition and
Treatment
Clyde E. Markowitz, MD
Clinical Case 1: Optimizing Treatment of a Patient With
Progressive MS
Clyde E. Markowitz, MD
Effect of Environmental Factors and Comorbidities: Impact on MS
Care
Bruce A. Cohen, MD
Rapid-Fire Controversies in MS
Stephen Krieger, MD
Clinical Case 2: Managing MS Patient in the COVID-19 Era – Tying
It All Together
Patricia K. Coyle, MD, FAAN, FANA
Panel Discussion
All Faculty
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY
Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Patient
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
Activity Details
1.75 ANCC Contact Hour(s)
Expires: November 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Physicians and APPs
Upon successful completion of this activity, physicians should be better able
to:
- Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
- Determine treatment for patients with RRMS or progressive MS based on evidence-based recommendations.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Nurses
Upon successful completion of this activity, nurses should be better able
to:
- Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
- Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
- Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Activity Description
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering the effect of environmental factors and comorbidities in patients with MS, advances in progressive MS, as well as rapid-fire controversies in MS. This session will also feature the patient perspective, with video segments of a patient with MS addressing common concerns and the role of shared decision-making.
Agenda
Introduction
Patricia K. Coyle, MD
Patient Perspectives in MS
Patricia K. Coyle, MD and Dana Hernandez
Advances in Progressive MS: Optimizing Patient Recognition and
Treatment
Clyde E. Markowitz, MD
Clinical Case 1: Optimizing Treatment of a Patient With
Progressive MS
Clyde E. Markowitz, MD
Effect of Environmental Factors and Comorbidities: Impact on MS
Care
Bruce A. Cohen, MD
Rapid-Fire Controversies in MS
Stephen Krieger, MD
Clinical Case 2: Managing MS Patient in the COVID-19 Era – Tying
It All Together
Patricia K. Coyle, MD, FAAN, FANA
Panel Discussion
All Faculty
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY
Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme
Faculty
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY
Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics
Patient
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech,
Genzyme, Janssen, Novartis, TG Therapeutics
Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.
Statement of Commercial Support
This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Contact Information for Questions About the Activity
CE Questions?
Contact us at CME@VindicoCME.com
A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis
StartActivity Details
Expires: June 20, 2023
Accredited By
The CME Institute of Physicians Postgraduate Press, Inc.
Target Audience
Neurology, neuromuscular, neuroimmunology, & neuro-ophthalmology advanced care practitioners in North America, Europe, and Japan
Learning Objectives
- Consider actions of novel medications in treatment decisions for patients with gMG (including IgG and AChR antibodies, FcRn modulation)
- Counsel patients on the changing landscape of gMG treatment
- Incorporate evidence on efficacy and safety into the process of tailoring appropriate therapies for patients with gMG, both with current treatments and as novel ones become available
Activity Description
On-demand webcast featuring faculty presentations and case questions from the webinar.
Statement of Educational Need
Treatment of gMG is not one-size-fits-all because of patients’ varied symptoms and disease pathophysiology. Despite numerous available therapies, the current treatment landscape for gMG has left many patients with unmet efficacy needs and considerable side effect burden. Research in gMG has grown substantially in recent years. Clinicians need awareness of disease mechanisms and education on the efficacy and safety of current and emerging therapies to improve outcomes for patients with gMG. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on gMG.
Chair
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada
Dr. Bril has served as a consultant for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen; received grant/research support from argenx, Alexion, UCB, Takeda, CSL, Immunovant, Momenta, Ionis, Pharnext; received honoraria from argenx, Alexion, Alnylam, Ackea, Immunovant, Momenta, Ionis, Pharnext; and has served on speakers/advisory boards for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen.
Faculty
University at Buffalo Jacobs School of Medicine and Biosciences
Buffalo, New York
Dr. Silvestri has served as a consultant for argenx and has served on speakers/advisory boards for Alexion, argenx, Immunovant, UCB, and Strongbridge.
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada
Dr. Barnett-Tapia has served as a consultant for argenx and Alexion; received grant/research support from the US Department of Defense, MGNet, Muscular Dystrophy Canada, and Grifols; and served on the speaker/advisory board for Sanofi.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., designates this
enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American
Academy of Physician Assistants (AAPA) accept certificates of participation
for educational activities certified for AMA PRA Category 1 Credit™
from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME
Posttest and Evaluation.
Instructions for Receiving Credit
In order to be awarded credit and/or a certificate for this activity, learners must study the material, participating in all course pages, complete the Posttest, and complete the Evaluation.
Statement of Commercial Support
Supported by an educational grant from argenx.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty members have determined that, to the best of their knowledge, corticosteroids, azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, IVIG, SCIG, PLEX, rituximab, rozanolixizumab, zilucoplan, nipocalimab, and RVT-1401 are not approved by the US Food and Drug Administration for the treatment of myasthenia gravis.
Contact Information for Questions About the Activity
cme@cmeinstitute.com
Activity Details
Expires: June 20, 2023
Accredited By
The CME Institute of Physicians Postgraduate Press, Inc.
Target Audience
Neurology, neuromuscular, neuroimmunology, & neuro-ophthalmology advanced care practitioners in North America, Europe, and Japan
Learning Objectives
- Consider actions of novel medications in treatment decisions for patients with gMG (including IgG and AChR antibodies, FcRn modulation)
- Counsel patients on the changing landscape of gMG treatment
- Incorporate evidence on efficacy and safety into the process of tailoring appropriate therapies for patients with gMG, both with current treatments and as novel ones become available
Activity Description
On-demand webcast featuring faculty presentations and case questions from the webinar.
Statement of Educational Need
Treatment of gMG is not one-size-fits-all because of patients’ varied symptoms and disease pathophysiology. Despite numerous available therapies, the current treatment landscape for gMG has left many patients with unmet efficacy needs and considerable side effect burden. Research in gMG has grown substantially in recent years. Clinicians need awareness of disease mechanisms and education on the efficacy and safety of current and emerging therapies to improve outcomes for patients with gMG. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on gMG.
Chair
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada
Dr. Bril has served as a consultant for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen; received grant/research support from argenx, Alexion, UCB, Takeda, CSL, Immunovant, Momenta, Ionis, Pharnext; received honoraria from argenx, Alexion, Alnylam, Ackea, Immunovant, Momenta, Ionis, Pharnext; and has served on speakers/advisory boards for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen.
Faculty
University at Buffalo Jacobs School of Medicine and Biosciences
Buffalo, New York
Dr. Silvestri has served as a consultant for argenx and has served on speakers/advisory boards for Alexion, argenx, Immunovant, UCB, and Strongbridge.
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada
Dr. Barnett-Tapia has served as a consultant for argenx and Alexion; received grant/research support from the US Department of Defense, MGNet, Muscular Dystrophy Canada, and Grifols; and served on the speaker/advisory board for Sanofi.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., designates this
enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American
Academy of Physician Assistants (AAPA) accept certificates of participation
for educational activities certified for AMA PRA Category 1 Credit™
from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME
Posttest and Evaluation.
Instructions for Receiving Credit
In order to be awarded credit and/or a certificate for this activity, learners must study the material, participating in all course pages, complete the Posttest, and complete the Evaluation.
Statement of Commercial Support
Supported by an educational grant from argenx.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty members have determined that, to the best of their knowledge, corticosteroids, azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, IVIG, SCIG, PLEX, rituximab, rozanolixizumab, zilucoplan, nipocalimab, and RVT-1401 are not approved by the US Food and Drug Administration for the treatment of myasthenia gravis.
Contact Information for Questions About the Activity
cme@cmeinstitute.com